FDA’s Drug Price Push in Biosimilar Plan Hinges on Other Reforms

The FDA’s effort to curb high drug costs by accelerating approvals of cheaper medicines similar to expensive biologics will ...

FDA rolls back 'red tape' in move aligned with Trump push to speed up new cures

FDA Commissioner Dr. Marty Makary announces the acceptance of broader real-world data in medical applications, ending ...
CBS News

FDA's plan to boost cheaper copycat drugs could stall at the patent office

While the FDA is streamlining regulation of copycat versions of the expensive drugs that millions take for arthritis, cancer, and other diseases, the U.S. patent office is making it harder for the ...
FierceBiotech

FDA moves to publish drug rejection letters in real time, releases new batch including Replimune's high-profile snub

The FDA today announced a plan to publicly release complete response letters at the same time they are issued to sponsoring companies, part of what the agency calls a push toward “radical transparency ...
MM&M

FDA’s plan to boost biosimilar drugs could stall at the patent office

While the FDA is streamlining regulation of copycat versions of the expensive drugs that millions take for arthritis, cancer, and other diseases, the U.S. patent office is making it harder for the ...
The Spokesman-Review

FDA’s plan to boost biosimilar drugs could stall at the patent office

News Nation/World FDA’s plan to boost biosimilar drugs could stall at the patent office Nov. 28, 2025 Updated Sat., Nov. 29, 2025 at 9:37 p.m. Food and Drug Administration (FDA) Commissioner Dr. Marty ...
Hosted on MSN

FDA's plan to boost cheaper copycat drugs could stall at patent office

While the FDA is streamlining regulation of copycat versions of the expensive drugs that millions take for arthritis, cancer, and other diseases, the U.S. patent office is making it harder for the ...